Skip to main content
. 2017 Dec 1;7(12):2587–2599.

Figure 3.

Figure 3

Kaplan-Meier survival curve of RAS wt BRAF wt mCRC. A. RASwt BRAFwt mCRC patients with high meEGFR ratio (≥ 0.23) had significantly worse PFS for anti-EGFR treatment (median PFS 5.3 mo, 95% CI 3.5-7 mo) compared with pts with the ratio < 0.23 (median PFS 8 mo, 95% CI 1.7-14.2 mo, P = 0.002). B. There was no correlation between high or low meEGFR expression in the tumor tissues and PFS for anti-EGFR treatment treatment (median PFS 7.4 mo, 95% CI 5.0-9.7 mo in low expression compared with median PFS 9.5 mo, 95% CI 2.9-16.0 mo in high expression, P = 0.46).